Lymphangioleiomyomatosis (LAM) is a rare lung disease found primarily in women and often affects other organs including lymph nodes and kidneys. LAM is caused by inactivating mutations in the tuberous sclerosis complex (TSC) genes (TSC1 and TSC2), resulting in activation of the mammalian target of rapamycin (mTOR) complex 1 (TORC1) signaling network. LAM can occur […]
GUILFORD, Conn., March 30, 2017 – LAM Therapeutics, a 4Catalyzer company that develops drugs for cancer and rare diseases, announced that it has closed $58M in Series C financing. 4Catalyzer is Connecticut’s premier biotechnology incubator and has raised over a quarter billion dollars to support its current class […]
GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment of rare diseases and cancer. LAM Therapeutics is a 4Catalyzer company. 4Catalyzer is Connecticut’s premier biotechnology […]
Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds […]